Tumor precision medication—individualized medication gene detection
Oncoscreen™ is a kind of high throughput sequencing technology researched and developed by Burn Rock itself, aiming at precise targeted treatment for tumor patients. Oncoscreen™ precisely selects 295 genes closely related to cancer occurrence mechanism and targeted treatment, fully covering various variations like mutation, insertion/deletion, copy number variation and fusion.
Oncoscreen™ can provide one-stop solution service for precise targeted treatment of cancer patients, the patented data analysis flow and professional medical team can accurately give description about the gene variations in targeted area, it can cover the whole-genome sequencing, exon sequencing and ultralow frequency mutations with clinical significance not included in RNA sequencing, to provide guidance for patients in looking for targeted therapy.
It aims at the tumor patients, and it adopts the advanced second generation sequencing technology to fully detect the gene variations relating to tumor targeted therapy and cancer occurrence/progression, so as to provide most comprehensive guidance for selection of targeted drug therapy schemes in clinic.
Oncoscreen™ genetic makeup:
65 target genes relating to targeted drugs
107 classic primary cancer/cancer suppressor genes
12 signaling pathways/regulatory genes of 123 tumors
In multi-gene detection, the definite clinical significance is the key, instead of the quantity of genes.
Oncoscreen™, based on currently scientific research and clinical data, precisely selects 295 genes relating to cancer occurrence, progression, medication and curative effects in solid tumors.
Partial targeted drugs covered in Oncoscreen™
Drugs on clinical trial